16d
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results